factual
Personalized Cancer Vaccine Cut Recurrence by Half
In a randomized phase two study of patients with early-stage skin cancer, a personalized mRNA vaccine given after surgery cut the recurrence rate of cancer by about 50 percent relative to standard of care.
factualpending
Speaker
Tal ZaksEvidence Quote
“when you give a personalized vaccine to those patients, it cuts the recurrence rate of cancer by about half, by about 50%, which is quite significant.”
Created: 11/19/2026, 4:01:33 PM
Your notes
Loading notes...